Tag Archives: Leah R. Cann

Analysts Are Bullish on These Healthcare Stocks: Celgene (CELG), Global Blood Therapeutics (GBT)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Celgene (CELG – Research Report), Global Blood Therapeutics (GBT – Research Report) and RedHill Biopharma (RDHL – Research Report) with bullish sentiments.

MEI Pharma (MEIP) Gets a Buy Rating from Oppenheimer

In a report released today, Leah R. Cann from Oppenheimer maintained a Buy rating on MEI Pharma (MEIP – Research Report), with a price target of $7.50. The company’s shares closed on Friday at $2.88. Cann commented: “Preclinical data for

Acceleron Pharma (XLRN) Gets a Hold Rating from Oppenheimer

Oppenheimer analyst Leah R. Cann maintained a Hold rating on Acceleron Pharma (XLRN – Research Report) today. The company’s shares opened today at $52.14. Cann observed: “While we have not modeled ACE-083 into our outlook for Acceleron by 2022, having

Oppenheimer Maintains a Hold Rating on Agios Pharma (AGIO)

Oppenheimer analyst Leah R. Cann maintained a Hold rating on Agios Pharma (AGIO – Research Report) today. The company’s shares opened today at $66.83. Cann said: “The updated data for AG-881 ongoing phase I study presented today include approximately three

Oppenheimer Maintains a Buy Rating on MEI Pharma (MEIP)

In a report released yesterday, Leah R. Cann from Oppenheimer maintained a Buy rating on MEI Pharma (MEIP – Research Report), with a price target of $7.50. The company’s shares closed yesterday at $3.42. Cann noted: “MEI Pharma’s loss per

Oppenheimer Remains a Buy on Loxo Oncology (LOXO)

Oppenheimer analyst Leah R. Cann maintained a Buy rating on Loxo Oncology (LOXO – Research Report) today and set a price target of $185. The company’s shares opened today at $173.73. Cann wrote: “Loxo’s lower than estimated 3Q18 loss resulted